While targeted immunotherapies such as anti-PD1/PDL1 have yielded substantial clinical outcomes for cancer treatment (63), we believe that the identification and validation of specific biomarkers may be of greater benefit to clinical treatment due to the differences between different immune cells and immune checkpoint marker genes. The gene discussed is CD274; the disease is cancer.